NYSE | TSX: ACB
LACHUTE, QC, Nov. 5, 2018 /CNW/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM), is pleased to
announce the official opening of its latest elite, high-tech
cannabis production facility in Lachute,
Quebec, known to the world as Aurora "Eau."
At 48,000 square feet, with 11 purpose-built grow rooms, Aurora
Eau will produce up to 4,500 kg of high quality cannabis per year,
all in a facility with some of the lowest electricity costs in
North America. It is designed to
grow niche varieties of cannabis for the premium medical and adult
consumer use markets in Quebec,
Canada and around the world. Eau becomes Aurora's second
production facility in Quebec, the
first being Aurora Vie, a 40,000 square foot indoor grow facility
in Pointe Claire, Quebec.
"We're thrilled to officially open our latest technologically
advanced facility in the Lachute Region and proud to continue to
invest in Quebec," said
Terry Booth, CEO of Aurora. "There
is incredible potential at Aurora Eau. It's designed to be a place
where our expert cannabis cultivators have the flexibility and
control to produce some very special high-end varieties that few
commercial growers are prepared to tackle. We intend to make some
very rare and exciting products there."
Designed and built to meet strict European Union GMP standards
and built mainly by local contractors, Aurora Eau is expected to
create more than 100 full-time jobs for local area residents. For
future development, it has additional manufacturing suites, which
allow for increased value-add production. Throughout the
construction phase of the project, Aurora injected more than
$12 million into the regional
community and will continue to support its economic development in
coming years, playing a key role in growing the local economy. The
facility is strategically located on 46 acres of land, which allows
for significant future expansion potential.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 500,000 kg per
annum and sales and operations in 19 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high quality product at low cost. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet EU GMP standards, and its
first production facility, the recently acquired MedReleaf Markham
facility, and its wholly owned European medical cannabis
distributor Aurora Deutschland, have achieved this level of
certification.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 15 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland , H2 Biopharma, Urban
Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed
Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia,
Agropro, Borela, and the pending acquisition of ICC Labs – Aurora
is distinguished by its reputation as a partner and employer of
choice in the global cannabis sector, having invested in and
established strategic partnerships with a range of leading
innovators, including: Radient Technologies Inc. (TSXV: RTI),
Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX:
CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings
Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group
(private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC:
CTTH), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur and include, but are not limited to the
variety of cannabis products that Aurora will supply to the adult
use market.. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made, and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX nor its Regulation Services Provider (as that term
is defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc.